Actively Recruiting
Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning
Led by State Institution "Republican Scientific and Practical Center" Cardiology, Belarus · Updated on 2025-11-25
500
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cerebral hyperperfusion syndrome (CHS) is a complication that can occur after carotid artery procedures like carotid endarterectomy or stenting. It involves symptoms such as severe headache, facial pain, vomiting, confusion, seizures, and even brain bleeding. CHS is more likely in patients whose cerebral blood flow increases significantly after revascularization. The exact cause is not fully understood, but it relates to impaired blood vessel regulation due to long-term reduced blood flow before treatment. This observational study evaluates patients undergoing carotid revascularization to predict the occurrence of CHS. Participants are divided into groups based on their cerebrovascular reserve status: reduced or sufficient. The study monitors patients after the procedure to identify signs of CHS within 30 days. Participants will be followed closely with clinical evaluations to detect CHS signs and symptoms. Researchers will measure how many develop CHS within the first month after surgery. The study includes various assessments to understand blood flow changes and complications. The total study period spans from the procedure through postoperative monitoring and follow-up to ensure safety and data collection.
CONDITIONS
Brief Title
Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 30 and 80 years
- Occlusive-stenotic lesion of the carotid arteries with indications for carotid revascularization
You will not qualify if you...
- Systemic vasculitis
- Cerebral vessel aneurysms
- Arteriovenous malformation of the brain
- Primary brain tumor (including metastatic lesions)
- Epilepsy
- History of traumatic brain injury
- Demyelinating diseases of the central nervous system
- History of neuroinfection
- Atrial fibrillation
- Frequent supraventricular or ventricular extrasystoles
- Chronic heart failure with left ventricular ejection fraction less than 40%
- Chronic kidney disease with estimated glomerular filtration rate less than 45 mL/min/1.73 m²
- Presence of an implanted cardioverter-defibrillator or pacemaker
- Presence of contraindications to the medical use of iodine-containing radiographic contrast agents
- Patient's unwillingness to continue participating in the study
- Absence of a temporal acoustic window for transcranial Doppler ultrasonography
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Procedure day
Participants undergo carotid revascularization as part of routine care.
1 visit (in-person)
Duration - 30 days
Participants are monitored for symptoms of cerebral hyperperfusion syndrome within 30 days after surgery.
Approximately 3 follow-up visits (in-person)
Trial Site Locations
Total: 1 location
1
State Institution "Republican Scientific and Practical Center "Cardiology"
Minsk, Belarus
Actively Recruiting
Research Team
I
Ivan Maiseyenka
H
Henadzi Popel
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here